A Randomized Phase Ii, Open Label, Study Of Daratumumab, Weekly Low-Dose Oral Dexamethasone And Cyclophosphamide With Or Without Pomalidomide In Patients With Relapsed And Refractory Multiple Myeloma
BLOOD（2020）
摘要
Introduction
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要